CHAPTER 1 INTRODUCTION

1.1. Key Benefits
1.2. Key Market Segments
1.3. Key Players
1.4. Research Methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. Key Findings Of The Study
2.2. CXO Perspective

CHAPTER 3 MARKET OVERVIEW

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top winning strategies

3.2.1.1. Competitive intelligence and strategies of companies

3.2.2. Top investment pockets

3.3. Market Share Analysis, 2015
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Growing elderly population
3.4.1.2. Increasing prevalence of spinal disorders
3.4.1.3. Advantages of biologic materials
3.4.1.4. Shift towards minimal invasive spine procedures

3.4.2. Restraints

3.4.2.1. Higher cost
3.4.2.2. Ethical issues related to grafting

3.4.3. Opportunities

3.4.3.1. Emerging markets to drive the demand for spine biologics

3.4.4. Impact analysis

3.5. Porter's Five Force's Analysis

3.5.1. Bargaining power of buyers
3.5.2. Bargaining power of suppliers
3.5.3. Threat of substitutes
3.5.4. Threat of new entrants
3.5.5. Competitive rivalry

3.6. Government Regulations

CHAPTER 4 GLOBAL SPINE BIOLOGICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.1.4. Global Spine Biologic Implantations, By Type
4.1.5. Spinal allografts

4.1.5.1. Market size and forecast

4.1.5.1.1. Machined bone allograft

4.1.5.1.1.1. Market size and forecast

4.1.5.1.2. Demineralized bone matrix

4.1.5.1.2.1. Market size and forecast

4.1.6. Bone graft substitutes

4.1.6.1. Market size and forecast

4.1.6.1.1. Bone morphogenetic proteins

4.1.6.1.1.1. Market size and forecast

4.1.6.1.2. Synthetic bone grafts

4.1.6.1.2.1. Market size and forecast

4.1.7. Cell based matrix

4.1.7.1. Market size and forecast

CHAPTER 5 GLOBAL SPINAL IMPLANTS AND DEVICES MARKET, BY SURGERY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. Open Spine Surgery

5.2.1. Market size and forecast

5.3. Minimally Invasive Spine Surgery

5.3.1. Market size and forecast

CHAPTER 6 GLOBAL SPINE BIOLOGICS MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size and forecast
6.2.5. Canada market size and forecast
6.2.6. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. France market size and forecast
6.3.5. Germany market size and forecast
6.3.6. UK market size and forecast
6.3.7. Spain market size and forecast
6.3.8. Italy market size and forecast
6.3.9. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. India market size and forecast
6.4.5. China market size and forecast
6.4.6. Japan market size and forecast
6.4.7. South Korea market size and forecast
6.4.8. Australia market size and forecast
6.4.9. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size and forecast
6.5.5. Saudi Arabia market size and forecast
6.5.6. South Africa market size and forecast
6.5.7. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ALPHATEC HOLDINGS, INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating product categories
7.1.4. Business Performance
7.1.5. Key strategic moves and developments

7.2. EXACTECH, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Key strategic share

7.3. JOHNSON & JOHNSON

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. GLOBUS MEDICAL, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating product categories
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Key strategy share

7.5. MEDTRONIC PLC

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Key strategy share

7.6. NUVASIVE, INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Key strategy share

7.7. ORTHOFIX INTERNATIONAL N.V.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Key strategy share

7.8. RTI SURGICAL, INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Key strategy share

7.9. SEASPINE

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Key strategy share

7.10. ZIMMER BIOMET HOLDINGS, INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Key strategy share

LIST OF TABLES

TABLE 1. GLOBAL SPINE BIOLOGICS MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 2. GLOBAL SPINE BIOLOGICS MARKET, BY REGION ($MILLION), 2014-2022
TABLE 3. GLOBAL SPINE BIOLOGICS IMPLANTATIONS, BY TYPE (THOUSAND UNITS), 2014-2022
TABLE 4. GLOBAL SPINAL ALLOGRAFT MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 5. GLOBAL BONE GRAFT SUBSTITUTES MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 6. GLOBAL SPINE BIOLOGICS MARKET, BY SURGERY TYPE ($MILLION), 2014-2022
TABLE 7. GLOBAL OPEN SPINE SURGERY MARKET, BY REGION ($MILLION), 2014-2022
TABLE 8. GLOBAL MINIMALLY INVASIVE SPINE SURGERY MARKET, BY REGION ($MILLION), 2014-2022
TABLE 9. GLOBAL SPINE BIOLOGICS MARKET, BY REGION ($MILLION), 2014-2022
TABLE 10. NORTH AMERICA SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 11. EUROPE SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 12. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 13. LAMEA SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 14. ALPHATEC: COMPANY SNAPSHOT
TABLE 15. ALPHATEC: PRODUCT CATEGORIES
TABLE 16. EXACTECH: COMPANY SNAPSHOT
TABLE 17. EXACTECH: BUSINESS SEGMENTS
TABLE 18. J&J: COMPANY SNAPSHOT
TABLE 19. J&J: BUSINESS SEGMENTS
TABLE 20. GLOBUS MEDICAL: COMPANY SNAPSHOT
TABLE 21. GLOBUS MEDICAL: PRODUCT CATEGORIES
TABLE 22. MEDTRONIC: COMPANY SNAPSHOT
TABLE 23. MEDTRONIC: BUSINESS SEGMENTS
TABLE 24. NUVASIVE: COMPANY SNAPSHOT
TABLE 25. NUVASIVE: BUSINESS SEGMENTS
TABLE 26. ORTHOFIX: COMPANY SNAPSHOT
TABLE 27. ORTHOFIX: BUSINESS SEGMENTS
TABLE 28. RTI: COMPANY SNAPSHOT
TABLE 29. RTI: BUSINESS SEGMENTS
TABLE 30. SEASPINE: COMPANY SNAPSHOT
TABLE 31. SEASPINE: BUSINESS SEGMENTS
TABLE 32. ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 33. ZIMMER BIOMET: BUSINESS SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL SPINE BIOLOGICS MARKET, BY TYPE ($MILLION), 2015 VS 2022
FIGURE 2. MARKET SEGMENTATION
FIGURE 3. TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4. TOP WINNING STRATEGIES, ORGANIC AND INORGANIC
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DEVELOPMENT STRATEGIES ADOPTED BY COMPANIES
FIGURE 7. TOP INVESTMENT POCKETS
FIGURE 8. MARKET SHARE ANALYSIS, 2015
FIGURE 9. LOW BACK PAIN HEALTH CARE VISITS PER 100 PERSONS, U.S., 2010
FIGURE 10. BARGAINING POWER OF BUYERS, 2015
FIGURE 11. BARGAINING POWER OF SUPPLIERS
FIGURE 12. THREAT OF SUBSTITUTES
FIGURE 13. THREAT OF NEW ENTRANTS
FIGURE 14. COMPETITIVE RIVALRY
FIGURE 15. SPINE BIOLOGICS MARKET FOR MACHINED ALLOGRAFTS ($MILLION), 2014-2022
FIGURE 16. SPINE BIOLOGICS MARKET FOR DEMINERALIZED BONE MATRIX ($MILLION), 2014-2022
FIGURE 17. SPINE BIOLOGICS MARKET FOR BMP ($MILLION), 2014-2022
FIGURE 18. SPINE BIOLOGICS MARKET FOR SYNTHETIC BONE GRAFTS ($MILLION), 2014-2022
FIGURE 19. SPINE BIOLOGICS MARKET FOR CELL BASED MATRIX ($MILLION), 2014-2022
FIGURE 20. FUSION PROCEDURES IN U.S.
FIGURE 21. DISTRIBUTION OF SPINE FUSION PROCEDURE BY SPINE SECTION FOR HOSPITAL DISCHARGE PATIENTS, U.S., 2011
FIGURE 22. U.S.: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 23. CANADA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 24. MEXICO: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 25. POPULATION STRUCTURE BY MAJOR AGE GROUPS, EU-28
FIGURE 26. FRANCE: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 27. GERMANY: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 28. UK: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 29. SPAIN: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 30. ITALY: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 31. REST OF EUROPE: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 32. INDIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 33. CHINA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 34. JAPAN: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 35. SOUTH KOREA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 36. AUSTRALIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 37. REST OF ASIA-PACIFIC: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 38. BRAZIL: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 39. SAUDI ARABIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 40. SOUTH AFRICA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 41. REST OF LAMEA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022

Spinal disorders such as spinal stenosis, spondylolisthesis, and scoliosis constitute a major proportion of health and economic burden, hence usage of effective spine biologics during spine surgery becomes a vital need for the treatment of the spinal disorders. To alleviate the aforementioned spine-related disorders and improve patient’s quality of life, spinal surgery is emerging as an ideal treatment option. Thus, rise in demand for spine surgery consequently drives the growth of spine biologics market, as biologics are widely adopted to promote fusion healing, which pedicle screws and rods are unable to provide.

Increase in incidences of spine-related disorders such as stenosis has led to the increase in the adoption of the spinal biologics. In addition, elimination of the need to harvest bone from the patient’s body in a secondary procedure, stimulation of the process of bone growth in spinal fusion surgery, shorter operating times, and reduced hospital stays fuel the growth of the market globally.

Advent of spine surgery treatment is one of the major factors that boosts the market growth. For instance, most of the spine surgeons these days prefer minimal invasive surgical techniques for a wide range of spine fusion procedures, which further use spine biologics. This is attributed to minor complications associated with the procedure such as reduced length of hospital stays and less bleeding.

Geographically, Asia-Pacific offers lucrative growth opportunity for the market due to growth in healthcare expenditure, increase in geriatric population, and rise in incidence of spine impairments. Thus, emerging economies (such as China & India) possess high potential for the market growth in spine biologics.